Screener
Zevra Therapeutics, Inc. ZVRA Business Segments
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Revenue, net by Product | ||||||
| MIPLYFFA | $30.2M+40.5% | $24.6M+43.9% | $26.4M+946% | $22.4M+787% | $21.5M+751% | |
| OLPRUVA | $200K-33.3% | $300K+200% | $300K+200% | $100K— | $300K— | |
| Segment long-lived assets by Geography | ||||||
| Europe | $300K-25.0% | $300K-25.0% | $400K-20.0% | $400K— | $400K— | |
| United States | $2M-23.1% | $1.2M— | $2.2M-83.6% | $2.2M— | $2.6M— |
FAQ
- How does Zevra Therapeutics, Inc. break its business down?
- Zevra Therapeutics, Inc. (ZVRA) reports revenue, net by product across 2 parts — MIPLYFFA and OLPRUVA. Each is extracted from the segment footnotes and tracked over time.
- Where does Zevra Therapeutics, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Zevra Therapeutics, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
